News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
POLICY
China Unveils the Final Drug List for the 7th Volume-based Procurement (VBP)
On July 18, China announced the official list of 327 products for the 7th volume-based procurement (VBP).The 327 products are owned by 217 bid-winning companies, which will supply the products to public health institutions. Among the companies, 6 are international enterprises—Hetero Labs, Bracco Sine, Almirall, Sandoz, and Pfizer.
Jul 25, 2022
REGULATION
Chinese Pharmacopoeia Commission Consults on 46 Packaging Material Standards
Since June 10, 2022, the Chinese Pharmacopoeia Commission has issued the drafts of 46 pharmaceutical packaging standards according to the plan for compiling the Chinese Pharmacopoeia 2025 Edition. The Commission is currently collecting public advice and comments on the drafts until Sept 1, 2022.
Jul 21, 2022
REGULATION
Chinese Pharmacopoeia Commission Seeks Public Advice on Colorant Standards
The Chinese Pharmacopoeia Commission is currently asking for public advice on colorant standards. The target colorants include but are not limited to colorants used in pediatric drugs, or widely used in pharmaceuticals, or whose current quality control standards are incomplete, especially for operation, and whose current standards cannot meet the need for medical use.
Jul 18, 2022
POLICY
327 Drug Products to Enter China's 7th Round of Volume-based Procurement (VBP)
Six international pharma companies--Hetero Labs, Bracco Sine, Almirall, Sandoz, Astellas, and Pfizer--won the bid in the preliminary result of the China's 7th round of volume-based procurement (VBP) of drugs.
Jul 15, 2022
PIPELINE
Licensing Deals Involving Chinese Pharma Companies in H1 2022
In H1 2022, China's pharma companies have taken part in multiple licensing deals. The in-licensing deals, in which Chinese companies are licensees, highlight AI-assisted drug R&D and COVID-19 vaccines/drugs.The out-licensing deals, in which Chinese companies were licensors, are mostly in the field of oncology.
Jul 14, 2022
Most Popular
- Monthly Report: New Drug Approvals in China | February 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
- Monthly Report: New Drug Approvals in China | March 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | March 2024
- China Consults on Self-Evaluation Report Guidance for Generic Drug Registration